Executives On The Move: New CEOs Appointed At Arcellx, KSQ Therapeutics
New board directors named at Eli Lilly, Immunicum, and Talaris Therapeutics.
You may also be interested in...
The company’s first candidate is a BCMA-targeting CAR-T, but Arcellx also is developing ARC T-cells controlled by a synthetic protein. Both have a binding domain that may confer better safety and efficacy than competitors.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Recent executive moves in the industry include C-suite changes at Amicus Therapeutics and Assembly Biosciences. Meanwhile, new directors were appointed at Torrent Pharmaceuticals and Perrigo, among others.